Zolgensma ‘Lottery’ Attacked From All Sides
Fears It Could Damage Pharma Industry’s Reputation
An unusual managed access program for Zolgensma designed by Novartis and AveXis has been attacked on ethical grounds, with critics claiming it does not properly allot the gene therapy to patients most in need. The companies have rejected the criticism, saying the program is fair and equitable.
You may also be interested in...
Novartis Targets Quick Launches For Zolgensma in Europe
The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.
Critical Juncture In Zolgensma EU Market Quest
If Zolgensma gets the thumbs up from the EMA this week, it will likely get formal EU approval within a couple of months.
Novartis ‘Urgently’ Working To Improve Zolgensma Access Program
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.